World Health Organization Raises Concern Over Acute Scarcity of Weight-Loss Medications
Less than 10% of people that would benefit from weight-loss injections including Wegovy have access to them, states the global health agency as it publishes its inaugural guidance on the therapies.
With more than one billion individuals worldwide currently classified as obese, it is calling for broader and more equitable availability to these injectable treatments.
According to projections, over two billion will be obese by 2030 if no action is taken.
"The latest guidance affirms that excess weight is a lifelong illness that can be treated with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major obstacles to widespread access to the jabs that can assist patients in reducing considerable body mass, says the organization.
Weight-Loss Drug Supply Crisis
Despite the current most favorable scenario, the supply of such drugs could only cover approximately 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice urges countries and companies to expand availability, via measures like voluntary licensing.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Operate
The injections imitate a body's own hormone to reduce digestion speed, curb appetite and boost satiety so individuals reduce food intake.
Patients typically begin shedding pounds within a few weeks of commencing the once-weekly jabs.
Studies suggests users may put most of the weight back on a year later of stopping the treatment, as their usual appetite resume.
To be above a healthy weight elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight concerns individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
